These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35905743)

  • 41. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
    Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RINT1 Regulates SUMOylation and the DNA Damage Response to Preserve Cellular Homeostasis in Pancreatic Cancer.
    Arnold F; Gout J; Wiese H; Weissinger SE; Roger E; Perkhofer L; Walter K; Scheible J; Prelli Bozzo C; Lechel A; Ettrich TJ; Azoitei N; Hao L; Fürstberger A; Kaminska EK; Sparrer KMJ; Rasche V; Wiese S; Kestler HA; Möller P; Seufferlein T; Frappart PO; Kleger A
    Cancer Res; 2021 Apr; 81(7):1758-1774. PubMed ID: 33531371
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epigenetic targeting DNMT1 of pancreatic ductal adenocarcinoma using interstitial control release biodegrading polymer reduced tumor growth through hedgehog pathway inhibition.
    Huang MH; Chou YW; Li MH; Shih TE; Lin SZ; Chuang HM; Chiou TW; Su HL; Harn HJ
    Pharmacol Res; 2019 Jan; 139():50-61. PubMed ID: 30385365
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice.
    Hedegger K; Algül H; Lesina M; Blutke A; Schmid RM; Schneider MR; Dahlhoff M
    Mol Oncol; 2020 Aug; 14(8):1653-1669. PubMed ID: 32335999
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): a novel AT2R agonist effectively attenuates growth of PDAC grafts in mice.
    Ishiguro S; Yoshimura K; Tsunedomi R; Oka M; Takao S; Inui M; Kawabata A; Wall T; Magafa V; Cordopatis P; Tzakos AG; Tamura M
    Cancer Biol Ther; 2015; 16(2):307-16. PubMed ID: 25756513
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
    Roca MS; Moccia T; Iannelli F; Testa C; Vitagliano C; Minopoli M; Camerlingo R; De Riso G; De Cecio R; Bruzzese F; Conte M; Altucci L; Di Gennaro E; Avallone A; Leone A; Budillon A
    J Exp Clin Cancer Res; 2022 Mar; 41(1):83. PubMed ID: 35241126
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma.
    Cox JL; Wilder PJ; Wuebben EL; Ouellette MM; Hollingsworth MA; Rizzino A
    Cancer Biol Ther; 2014 Aug; 15(8):1042-52. PubMed ID: 24841553
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma.
    Vaz AP; Deb S; Rachagani S; Dey P; Muniyan S; Lakshmanan I; Karmakar S; Smith L; Johansson S; Lele S; Ouellette M; Ponnusamy MP; Batra SK
    Oncotarget; 2016 Jan; 7(3):3317-31. PubMed ID: 26689992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent advances in proteomically subtyping pancreatic ductal adenocarcinomas and their potential clinical impact.
    Roesli C
    Expert Rev Proteomics; 2015 Feb; 12(1):5-8. PubMed ID: 25407217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment.
    Huang Y; Nahar S; Nakagawa A; Fernandez-Barrena MG; Mertz JA; Bryant BM; Adams CE; Mino-Kenudson M; Von Alt KN; Chang K; Conery AR; Hatton C; Sims RJ; Fernandez-Zapico ME; Wang X; Lillemoe KD; Fernández-Del Castillo C; Warshaw AL; Thayer SP; Liss AS
    Clin Cancer Res; 2016 Aug; 22(16):4259-70. PubMed ID: 27169995
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma.
    Li JT; Yin M; Wang D; Wang J; Lei MZ; Zhang Y; Liu Y; Zhang L; Zou SW; Hu LP; Zhang ZG; Wang YP; Wen WY; Lu HJ; Chen ZJ; Su D; Lei QY
    Nat Cell Biol; 2020 Feb; 22(2):167-174. PubMed ID: 32029896
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.
    Kaneda MM; Cappello P; Nguyen AV; Ralainirina N; Hardamon CR; Foubert P; Schmid MC; Sun P; Mose E; Bouvet M; Lowy AM; Valasek MA; Sasik R; Novelli F; Hirsch E; Varner JA
    Cancer Discov; 2016 Aug; 6(8):870-85. PubMed ID: 27179037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A nicotine-induced positive feedback loop between HIF1A and YAP1 contributes to epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma.
    Ben Q; An W; Sun Y; Qian A; Liu J; Zou D; Yuan Y
    J Exp Clin Cancer Res; 2020 Sep; 39(1):181. PubMed ID: 32894161
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inactivity of Peptidase ClpP Causes Primary Accumulation of Mitochondrial Disaggregase ClpX with Its Interacting Nucleoid Proteins, and of mtDNA.
    Key J; Torres-Odio S; Bach NC; Gispert S; Koepf G; Reichlmeir M; West AP; Prokisch H; Freisinger P; Newman WG; Shalev S; Sieber SA; Wittig I; Auburger G
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943861
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interleukin-17 activates and synergizes with the notch signaling pathway in the progression of pancreatic ductal adenocarcinoma.
    Wang X; Chen H; Jiang R; Hong X; Peng J; Chen W; Jiang J; Li J; Huang D; Dai H; Wang W; Lu J; Zhao Y; Wu W
    Cancer Lett; 2021 Jun; 508():1-12. PubMed ID: 33713738
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure of Staphylococcus aureus ClpP Bound to the Covalent Active-Site Inhibitor Cystargolide A.
    Illigmann A; Vielberg MT; Lakemeyer M; Wolf F; Dema T; Stange P; Kuttenlochner W; Liebhart E; Kulik A; Staudt ND; Malik I; Grond S; Sieber SA; Kaysser L; Groll M; Brötz-Oesterhelt H
    Angew Chem Int Ed Engl; 2024 Jan; 63(3):e202314028. PubMed ID: 38029352
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
    Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
    Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dysbindin promotes pancreatic ductal adenocarcinoma metastasis by activating NF-κB/MDM2 via miR-342-3p.
    Zhu D; Zheng S; Fang C; Guo X; Han D; Tang M; Fu H; Jiang M; Xie N; Nie Y; Yao X; Chen Y
    Cancer Lett; 2020 May; 477():107-121. PubMed ID: 32120026
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity.
    Si W; Liu X; Wei R; Zhang Y; Zhao Y; Cui L; Hong T
    Cell Death Dis; 2019 Feb; 10(3):206. PubMed ID: 30814496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of MRP4/ABCC4 as a Target for Reducing the Proliferation of Pancreatic Ductal Adenocarcinoma Cells by Modulating the cAMP Efflux.
    Carozzo A; Yaneff A; Gómez N; Di Siervi N; Sahores A; Diez F; Attorresi AI; Rodríguez-González Á; Monczor F; Fernández N; Abba M; Shayo C; Davio C
    Mol Pharmacol; 2019 Jul; 96(1):13-25. PubMed ID: 31043460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.